Guidelines on Diagnosis and Treatment of Malignant Lymphomas
Guidelines on Diagnosis and Treatment of Malignant Lymphomas
Guidelines on Diagnosis and Treatment of Malignant Lymphomas
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Immunohistochemistry (IHC)<br />
Hodgkin Lymphoma (HL)<br />
BASIC IHC PANEL ON FFPET (Formalin fixed, paraffin-embedded tissue)<br />
- CD45<br />
- CD3<br />
- CD20<br />
- CD15<br />
-CD30<br />
- EMA (EMA should be negative in classic HL; positive in NLPHL)<br />
IF H&E MORPHOLOGY IS TYPICAL<br />
CD45<br />
CD3<br />
CD20<br />
CD15<br />
CD30<br />
CD3<br />
CD20<br />
CD15<br />
CD30<br />
}<br />
}<br />
.......................NEGATIVE<br />
.......................POSITIVE<br />
}<br />
.......................NEGATIVE<br />
}<br />
.......................NEGATIVE<br />
.......................POSITIVE<br />
}<br />
.....................HL<br />
C<strong>on</strong>sider ALCL<br />
Perform ALK1<br />
If ALK 1 NEG<br />
If ALK 1 POS<br />
................................................................HL<br />
................................................................ALCL<br />
IF H&E MORPHOLOGY IS ATYPICAL ADD THE FOLLOWING TO THE INITIAL BASIC IHC PANEL<br />
CD79A<br />
CD5<br />
CD10<br />
ALK 1<br />
Myeloperoxidase – to exclude myeloid origin.<br />
MCT – to exclude mast cell origin.<br />
N<strong>on</strong>-lymphoid markers as appropriate e.g. to exclude – Germ Cell tumours<br />
<strong>Malignant</strong> melanoma<br />
Poorly differentiated carcinoma<br />
7
Change language